Skip to main content

HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).

Publication ,  Conference
Seligmann, JF; Elliott, F; Jacobs, B; Hatch, AJ; Sibley, A; Richman, S; Jiang, C; Barrett, J; Owzar, K; Quirke, P; Hurwitz, H; Seymour, MT; Nixon, AB
Published in: Journal of Clinical Oncology
May 20, 2015

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

3583 / 3583

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Seligmann, J. F., Elliott, F., Jacobs, B., Hatch, A. J., Sibley, A., Richman, S., … Nixon, A. B. (2015). HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In Journal of Clinical Oncology (Vol. 33, pp. 3583–3583). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.3583
Seligmann, Jenny F., Faye Elliott, Bart Jacobs, Ace Joseph Hatch, Alexander Sibley, Susan Richman, Chen Jiang, et al. “HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).” In Journal of Clinical Oncology, 33:3583–3583. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3583.
Seligmann JF, Elliott F, Jacobs B, Hatch AJ, Sibley A, Richman S, et al. HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 3583–3583.
Seligmann, Jenny F., et al. “HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 3583–3583. Crossref, doi:10.1200/jco.2015.33.15_suppl.3583.
Seligmann JF, Elliott F, Jacobs B, Hatch AJ, Sibley A, Richman S, Jiang C, Barrett J, Owzar K, Quirke P, Hurwitz H, Seymour MT, Nixon AB. HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 3583–3583.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

3583 / 3583

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences